Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy-Reference-Cited by-同舟云学术

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

Published:2016-03 Issue: Volume:93 Page:95-103
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Pérol Maurice,Ciuleanu Tudor-Eliade,Arrieta Oscar,Prabhash Kumar,Syrigos Konstantinos N.,Goksel Tuncay,Park Keunchil,Kowalyszyn Ruben Dario,Pikiel Joanna,Lewanski Conrad R.,Thomas Michael,Dakhil Shaker,Kim Joo-Hang,Karaseva Nina,Yurasov Sergey,Zimmermann Annamaria,Lee Pablo,Carter Gebra Cuyun,Reck Martin,Cappuzzo Federico,Garon Edward B.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

2. Impact of the new lung cancer staging system for a predominantly advanced-disease patient population;Chien;J. Thorac. Oncol.,2010

3. Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study;Carrato;Curr. Med. Res. Opin.,2014

4. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008

5. Are the most distressing concerns of patients with inoperable lung cancer adequately assessed? A mixed-methods analysis;Tishelman;J. Clin. Oncol.,2010

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-line therapy in advanced non–small cell lung cancer;Lung Cancer;2024

2. WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer;Cureus;2023-10-19

3. Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne;Revue des Maladies Respiratoires Actualités;2023-10

4. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review;Frontiers in Oncology;2023-09-04

5. Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis;Frontiers in Oncology;2023-03-21